Skip to main content
. 2013 Jan 25;8(1):e53131. doi: 10.1371/journal.pone.0053131

Figure 3. Inhibition of IL-17A in tumor sites promotes CTLs activation, especially in the tumor microenvironment.

Figure 3

The cytotoxicity assay used CD8+ T cells from splenocytes or TILs in MC38 subcutaneous tumor treated Ad-si-IL-17 and Ad-SNC. (A) The cytotoxic activities against MC38 cells of CD8+ T cells from splenocytes in mice treated with intratumoral injection of Ad-si-IL-17 were almost the same as those in control mice (n = 5). The cytotoxic activities against B16 cells were less than 10% in both groups (n = 5). (B) The cytotoxic activities against MC38 cells in CD8+ T cells from TILs in mice treated with intratumoral injection of Ad-si-IL-17 were significantly higher than those with Ad-SNC (n = 3). Data are representative of two independent experiments. Data are presented as means ± SE. *P<0.05, Mann-Whitney test.